Chemed's pre-earnings short build has started to unwind. Jefferies upgraded CHE to Buy on Wednesday, raising its target 19% to $620 and pointing to a VITAS hospice rebound in 2026 and improving margins as the key drivers. The upgrade lands one day after Chemed reported Q3 results. The stock rose 4.8% on October 28, its strongest single-day move in recent months, and is up 4.3% on…
CHE Jefferies upgrades to Buy from Hold, raises target 19% to $620, citing VITAS rebound prospects in 2026 and improving margins.
Key data as of 3 Nov 2026
CHE Jefferies upgrades to Buy from Hold, raises target 19% to $620, citing VITAS rebound prospects in 2026 and improving margins.
CHE short interest surges 20.3% in one week to 4.9% of float, driven by 7.6% jump in one day. Earnings report due tomorrow.
Chemed Corporation reports third-quarter results today, with short sellers having quietly built their largest position of the past month in the days immediately before the release. Short interest climbed 20% over the…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for CHE — free to start on ORTEX.
Sign up for free →Open CHE on ORTEX